

S/N 09/754,826

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Mohamed E. El Halawani et al.

Examiner: Unknown


Serial No.: 09/754,826

Group Art Unit: Unknown

Filed: January 4, 2001

Docket: 600.492US1

Title: USE OF PASSIVE MYOSTATIN ANALOGS IN THERAPY



**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the "Notice to File Missing Parts of Nonprovisional Application" mailed May 11, 2001, please amend the above-identified patent application as follows:

**In the Specification**

Please enter the enclosed SEQUENCE LISTING into the specification.

Please substitute the paragraph in the appendix entitled "Clean Version of the First Full Paragraph of Page 46" for the first full paragraph of page 46 of the specification. Specific amendments to this paragraph are detailed in the following marked-up paragraph:

Myostatin peptides were prepared. The peptides were C1 (Asn-Met-Leu-Tyr-Phe-Asn-Gly-Lys-Glu-Gln-Ile-Ile-Tyr-Gly-Lys-Ile; residues 83-98 [residues 5-15]; SEQ ID NO:4), D1 (Asp-Cys-Asp-Glu-His-Ser-Thr-Glu-Ser-Arg-Cys; residues 5-15 [residues 33-41]; SEQ ID NO:5), and E1 (Ile-Ala-Pro-Lys-Arg-Tyr-Lys-Ala-Asn; residues 33-41 [residues 83-98]; SEQ ID NO:6). Each received a peptide immunogen and the sequences were chosen based on relative hydrophilicity/hydrophobicity.

**Remarks**

This Preliminary Amendment and the above-referenced SEQUENCE LISTING are filed in part to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 - 1.825. In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted SEQUENCE LISTING in ASCII computer readable form is also submitted herewith. The contents of the paper version of the SEQUENCE LISTING and the computer readable form being submitted herewith are the same, and the paper copy of the SEQUENCE LISTING and the computer readable form of the SEQUENCE LISTING do not include new matter.

PRE AMEND/A  
AJ  
PT#4  
2-22-02

09754826-101601